Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M
Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility.